VAXNEUVANCE Pediatrics

Electronic Health Record (EHR)

Vaxneuvance™ Pneumococcal 15-valent Conjugate Vaccine



To begin administering VAXNEUVANCE, ensure that the product is available in your EHR system.

It can take time for new vaccines to appear in EHR product lists. If VAXNEUVANCE is not yet available in the EHR, it can be added manually. This will allow for a timelier transition to VAXNEUVANCE while helping to maintain accuracy in patient records.

To learn how to manually add VAXNEUVANCE to your EHR system, refer to your internal or external EHR support resources.

Keep in mind that EHR security privileges tend to vary depending on practice size. The below list may help you determine who, among your staff, is most likely able to manually add VAXNEUVANCE:

SMALL PRACTICE
the physician or practice administrator

MID-SIZED PRACTICE
system administrator, nurse, or any EHR super user

LARGE PRACTICE
an IT staff member, clinical manager, or system administrator

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status and the potential benefits and possible risks.

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

MERCK